Publications

Authors:

Caminati, Marco; Crisafulli, Ernesto; Lunardi, Claudio; Micheletto, Claudio; Festi, Giuliana; Maule, Matteo; Giollo, Alessandro; Orsolini, Giovanni; Senna, Gianenrico

Title:

Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Year:

2021

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE

ISSN of journal:

2213-2198

N° Volume:

9

Number or Folder:

3

Page numbers:

1386-1388

Keyword:

Mepolizumab, severe asthma, EGPA

Short description of contents:

In patients with eosinophilic granulomatosis with polyangiitis in remission phase and persisting severe steroid-dependent asthma, mepolizumab 100 mg/4 wk prevents vasculitis relapse and maintains asthma control. An “asthma-tailored” dose may be considered in the maintenance phase of eosinophilic granulomatosis with polyangiitis as a steroid/immunosuppressive-sparing agent.

Product ID:

116753

Handle IRIS:

11562/1027040

Last Modified:

November 15, 2022

Bibliographic citation:

Caminati, Marco; Crisafulli, Ernesto; Lunardi, Claudio; Micheletto, Claudio; Festi, Giuliana; Maule, Matteo; Giollo, Alessandro; Orsolini, Giovanni; Senna, Gianenrico, Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase «JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE» , vol. 9 , n. 3 , 2021 , pp. 1386-1388

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo